

Wellington Emerging Markets Health Care Equity Fund



CHF UN Accumulating Hedged

RISK AND REWARD PROFILE

1 2 3 4 5 6 7
Lowest Risk Highest Risk

Capital at risk: please refer to the bottom of this page for details about the Risk & Reward Profile.

FUND DETAILS

Fund Inception: December 2021 Share Class Inception: December 2021 Fund Assets: USD 977,879.6 NAV: CHF 7.65

KEY INFORMATION

Domicile: Luxembourg
Regulatory Regime: UCITS
Legal Structure: Corporate SICAV
Dealing Frequency: Daily

Country Registration: Austria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Singapore*, Spain, Sweden, Switzerland, United Kingdom.

ISIN: LU2404422722 Bloomberg: WECUNAC LX Sedol: BPG96V8 Lipper: 68689594 WKN: A3C9.14

*Restricted scheme

FUND CHARACTERISTICS

Asset-Weighted Market Capitalisation:

USD 8.8 billion

Beta (Projected)*: Tracking Risk (Projected, Annualised)*: 0.89 8.4%

*Source: Wellington Noether Model (projected figures)

FEES AND PRICING

Minimum Investment: USD 5,000 Management Fee: 0.75% p.a. Ongoing Charges Figure *: 1.10%

*The ongoing charges figure excludes Fund transaction costs, except in the case of depositary fees and an entry/exit charge paid by the Fund when buying or selling Shares in another collective investment undertaking. A more detailed description of the charges that apply to the Fund is set out in the section "Charges and Expenses" in the Prospectus. The ongoing charges figure may change over time. Charges applied will reduce the return potential of investments.

If an investor's own currency is different from the currency shown, costs could increase or decrease due to currency or exchange related fluctuations.

For more information, please visit **www.wellingtonfunds.com**

SUMMARY OF INVESTMENT OBJECTIVE

The Wellington Emerging Markets Health Care Equity Fund is actively managed and seeks long-term total returns in excess of the S&P BMI Emerging Markets Health Care Index, primarily investing in health care companies located in or deriving a significant proportion of revenue from emerging and frontier markets.

FUND PERFORMANCE (%)

The inception date of the CHF UN Acc Hdg share class is 16 December 2021. | Past performance is not shown until the share class has a one year performance record.

FUND MANAGEMENT



Rebecca Sykes, CFA 17 years of experience



Ann Gallo 33 years of experience

WHAT ARE THE RISKS?

CAPITAL: Investment markets are subject to economic, regulatory, market sentiment and political risks. All investors should consider the risks that may impact their capital, before investing. The value of your investment may become worth more or less than at the time of the original investment. The Fund may experience a high volatility from time to time.

CONCENTRATION: Concentration of investments within securities, sectors or industries, or geographical regions may impact performance.

CURRENCY: The value of the Fund may be affected by changes in currency exchange rates. Unhedged currency risk may subject the Fund to significant volatility.

EMERGING MARKETS: Emerging markets may be subject to custodial and political risks, and volatility. Investment in foreign currency entails exchange risks.

EQUITIES: Investments may be volatile and may fluctuate according to market conditions, the performance of individual companies and that of the broader equity market.

HEDGING: Any hedging strategy using derivatives may not achieve a perfect hedge.

INVESTMENT IN CHINA: Changes in Chinese political, social or economic policies or securities law and regulations may significantly affect the value of the Fund. Chinese securities may be subject to trading suspensions which could impact the Funds investment strategy and affect performance. Chinese tax law is applied under policies that may change without notice and with retrospective effect.

MANAGER: Investment performance depends on the investment management team and their investment strategies. If the strategies do not perform as expected, if opportunities to implement them do not arise, or if the team does not implement its investment strategies successfully; then a fund may underperform or experience losses.

SHANGHAI-HONG KONG STOCK CONNECT: Allows access to certain China A Shares listed on the Shanghai and the Shenzhen Stock Exchanges, securities could be recalled from the scope of the program which could restrict the Funds ability to implement its investment strategy effectively. The program is subject to quota limitations which may restrict dealing on a timely basis. Trading is subject to China A Share market rules, foreign shareholder restrictions and disclosure obligations and changes to laws, regulations and policies in China may affect share prices of securities held.


SUSTAINABILITY: A Sustainability Risk can be defined as an environmental, social or governance event or condition that, if it occurs, could cause an actual or potential material negative impact on the value of an investment.

Before subscribing, please refer to the Fund offering documents/prospectus for further risk factors and pre-investment disclosures. For the latest NAV, please visit www.fundinfo.com.

GEOGRAPHIC BREAKDOWN

China 54.5 Brazil 5.2 India 7.9 22.8 United Kingdom 0.7 7.4 Thailand 4.2 2.7 2.0 Hungary 2.8 0.8 2.7 0.2 1.5 Indonesia 2.4 1.5 0.0 0 15 30 45 60

SECTOR DISTRIBUTION



Totals may not add up to 100% due to rounding

Benchmark

Totals may not add up to 100% due to rounding.

TOP 10 HOLDINGS

Fund

COMPANY NAME	MARKET	INDUSTRY	% OF EQUITY
iShares MSCI India	India	Pooled Vehicle	7.9
CSPC Pharmaceutical	China	Pharma, Biotech & Life Sciences	7.0
Shandong Weigao Grou	China	Health Care Equipment & Services	6.2
Shenzhen Mindray	China	Health Care Equipment & Services	5.3
Hapvida Participacoe	Brazil	Health Care Equipment & Services	5.1
MediClinic Intl Plc	United Kingdom	Health Care Equipment & Services	5.0
Hangzhou Tigermed Co	China	Pharma, Biotech & Life Sciences	4.8
Bangkok Dusit Medica	Thailand	Health Care Equipment & Services	4.2
Yifeng Pharmacy Chai	China	Food & Staples Retailing	4.1
Hypera SA	Brazil	Pharma, Biotech & Life Sciences	3.8
Total of Top 10			53.4
Number of Equity Names			39

The individual issuers listed should not be considered a recommendation to buy or sell. The weightings do not reflect exposure gained through the use of derivatives. Holdings vary and there is no guarantee that the Fund will hold any of the securities listed. Please refer to the annual and semi-annual report for the full holdings.